Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Primary Industries
- Drugs
- Therapeutic
- Biotechnology
- Pharmaceuticals
- Disease
- Diagnostic
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 28912
License Grant
Licensor hereby grants an exclusive, worldwide license under the Licensor Know-How, the Licensee's Patent Rights and the Licensor's Patent Rights to make, have made, import, use, offer for sale and sell Licensed Products. Licensee may sublicense the Licensor's Know-How, the Licensee's Patent Rights and the Licensor's Patent Rights to an entity that, in the reasonable business judgment of Licensee, is capable of performing such sublicense.
License Property
Licensor has developed and acquired proprietary patent rights and know-how relating to peptides useful in the inhibition or disassembly of amyloid aggregation or prion formation and that could be useful as therapeutic agents in the treatment of diseases associated with amyloid or prion formation either per se, as analogs thereof or as peptidomimetics developed on the basis of structural leads derived from such peptides.
Amyloidosis is a condition in which an abnormal protein called amyloid builds up in your tissues and organs. When it does, it affects their shape and how they work. Amyloidosis is a serious health problem that can lead to life-threatening organ failure.
US
AMYLOID AGGREGATION INHIBITORS
PENDING
766596
12/12/1996
US
AMYLOID AGGREGATION INHIBITORS
PENDING/ ABANDONED
478326
6/6/1995
US
AMYLOID AGGREGATION INHIBITORS
GRANTED
630045
10/4/1996
WO
AMYLOID AGGREGATION INHIBITORS
NATIONAL'D
96US10220
6/6/1996
US
AMYLOID AGGREGATION INHIBITORS ANALOGS
PENDING
5/11/1999
IPSCIO Record ID: 27209
License Grant
The Company hereby grants to a Netherlands Licensee an exclusive, worldwide right to its proprietary patent rights and know how relating to peptides useful in the inhibition or disassembly of amyloid aggregation or prion formation and that could be useful as therapeutic agents in the treatment of diseases associated with amyloid or prion formation either per se, as analogs thereof or as peptidomimetics developed on the basis of structural leads derived from such peptides; and desires to evaluate the know-how and patent rights by nitiating and diligently conducting a research program that is defined below and further desires to have the right during the term of this Agreement to obtain a worldwide, exclusive license under the know-how and/or patent rights.
License Property
The Company has developed and acquired proprietary patent rights and know how relating to peptides useful in the inhibition or disassembly of amyloid aggregation or prion formation and that could be useful as therapeutic agents in the treatment of diseases associated with amyloid or prion formation either per se, as analogs thereof or as peptidomimetics developed on the basis of structural leads derived from such peptides.
Field of Use
The rights granted apply to the healthcare industry.
IPSCIO Record ID: 29228
License Grant
The Licensee acquired an exclusive license, under patent rights and know-how controlled by the Licensor, government organization, to develop, make, use and sell in the United States and its territories a class of peptides and related compounds to inhibit the formation of amyloid fibrils.
License Property
ANL-IN-99-019 & ANL-IN-00-019 filed as USPTO application no. 09/712,819 entitled A Fibril-Blocking Peptide, A Method for Preventing Fibril Formation.
Field of Use
Licensee desires to acquire rights in and to said Inventions for drug development.
These fibrils are implicated in a number of diseases such as Alzheimer's disease and amyloidosis.
IPSCIO Record ID: 6502
License Grant
The University & Government Organization grants the Licensee, the exclusive right and license in the Licensed Patent, with the right to further sublicense, to make, have made, use, and sell, have sold Licensed Products in the United States, its territories, and possessions in the Field of Use.
Field of Use
The Field of Use is the prevention of protein aggregation.
IPSCIO Record ID: 28812
License Grant
UTRF, the University hereby grants to Irish Licensee (a) an exclusive (even as to UT and UTRF, subject to any rights expressly reserved in this Agreement), research and commercial right and license in the Field of Use, with the right to grant Sublicenses, under UTRF’s rights in Licensed Patents to practice under the Licensed Patents; and (b) an exclusive (even as to UT and UTRF, subject to any rights expressly reserved in this Agreement), commercial right and license in the Field of Use, with the right to grant Sublicenses, to utilize the Licensed Know-How for the purpose of practicing under the Licensed Patents (collectively, the License).
License Property
Licensed Patents
U.S. Patent Application # 11/966,988, titled Treatment and Prophylaxis of Amyloidosis
PCT International Application No. PCT/US07/089169, titled Treatment and Prophylaxis of Amyloidosis.
In medicine, amyloidosis refers to a variety of conditions wherein normally soluble proteins become insoluble and are deposited in the extracellular space of various organs or tissues, disrupting normal function.
The Licensee jointly own with the Licensor patent applications pending in the United States Australia, Brazil, China, Colombia, Eurasia, Europe, Hong Kong, Indonesia, Israel, India, Japan, South Korea, Mexico, Norway, New Zealand, Philippines, Singapore and South Africa, and have exclusively licensed the joint ownership interest in these patent applications.
Field of Use
Field of Use means any and all diagnostic or therapeutic applications directed toward identification or treatment of disease.
IPSCIO Record ID: 209544
License Grant
Licensor grants to the German Licensee an exclusive, except as to Licensor, right and license in the Territory during the Exclusivity Period, under the Licensors Information and Patent Rights, to develop Licensees Compounds, and to develop, manufacture or have manufactured, use and sell or have sold Licensees Compounds as incorporated into a Licensee Product.
License Property
Licensors product means any pharmaceutical preparation containing a Licensor Compound, whether as the sole active ingredient or mixed with any other active ingredient and which is intended for prophylactic or therapeutic purposes.
Licensee product means any pharmaceutical preparation or product containing a Licensee Compound, whether as the sole active ingredient or mixed with any other active ingredient.
Licensee Compound means and includes any of any compound which is screened by Licensor and exhibits AAI, or amyloid aggregation inhibition, activity in any of such screens or any compound which is developed by Licensee utilizing, or is based upon, any Licensor Information.
Patent 08/404,831 – Modulators of beta-amyloid peptide aggregation
The present invention provides ß amyloid modulators that affect the aggregation of natural ß-amyloid and therefore can be used to treat subjects having a disorder associated with ß-amyloidosis, e.g. Alzheimer's disease (AD). The aggregation and deposition of ß-amyloid play an important role in the pathology of AD. The modulators of the present invention can affect aggregation of natural ß amyloid peptides when present at a lower concentration than that of the natural ß amyloid peptides and further are suitable for therapeutic use in vivo.
Field of Use
This agreement is solely for use as a prophylactic or therapeutic or as a diagnostic solely to the extent that any such Licensee Compound is required as a diagnostic in order to commercialize a Licensee Compound, and sell the corresponding Licensee Product, as a prophylactic or therapeutic.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
